POPULARITY
8 episodes with pten
5 episodes with pten
3 episodes with pten
4 episodes with pten
3 episodes with pten
5 episodes with pten
3 episodes with pten
2 episodes with pten
2 episodes with pten
Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generation sequencing receives relugolix/darolutamide with chemotherapy and experiences PSA decline that plateaus at approximately 1 ng/mL — Rana R McKay, MD, FASCO (10:29) CME information and select publications
Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that progressed to metastatic HSPC with PTEN loss by next-generation sequencing of primary archival tissue from 2017 receives abiraterone for 2 years — Rana R McKay, MD, FASCO (8:26) CME information and select publications
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy. Key topics include: Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA Using biomarkers such as BRCA1/2, PIK3CA, AKT1, PTEN, and ESR1 to guide therapy in metastatic disease Monitoring and managing treatment-related adverse events, including neutropenia, diarrhea, hepatotoxicity, QTc prolongation, hyperglycemia, rash, stomatitis, anemia, nausea, and fatigue Using dose modification, supportive care, patient education, and proactive follow-up to improve adherence and persistence with oral therapy Incorporating oncology pharmacists and the multidisciplinary care team into ongoing treatment monitoring and patient support PresentersDanielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program: Link to full program:https://bit.ly/4gvZerW And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios. Early Breast Cancer:https://bit.ly/4gtUiUq AKT or PI3K Inhibitors in MBC:https://bit.ly/4qcyBvk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
En este episodio del Foro Abierto de ScienceLink, el Dr. Augusto Ferreyra y la Dra. Carolina Passarella, especialistas en urooncología, analizan los debates y conclusiones más relevantes de la Conferencia de Consenso sobre Cáncer de Próstata Avanzado, celebrada en Lugano, Suiza. La conversación se centra en dilucidar las "zonas grises" del manejo del cáncer de próstata, presentando el posicionamiento actual de los expertos internacionales frente a escenarios clínicos donde la evidencia de estudios fase III aún está en evolución, lo cual tiene un impacto directo en la toma de decisiones terapéuticas de la práctica diaria.El análisis clínico aborda, en primer lugar, las estrategias de desintensificación en la enfermedad localizada de alto riesgo. Se discute la tendencia a abandonar el estándar histórico de 36 meses de terapia de deprivación androgénica en favor de esquemas de 18 a 24 meses, buscando un mejor equilibrio entre el beneficio oncológico y la preservación de la salud cardiovascular, ósea y muscular del paciente. Asimismo, los ponentes debaten el abordaje de la recaída bioquímica y la persistencia de enfermedad post-prostatectomía, enfatizando la recomendación de iniciar radioterapia de rescate temprano sin postergar la decisión a la obtención de un resultado positivo en la PET-PSMA, dada la baja sensibilidad del método ante niveles ínfimos de antígeno prostático específico.Finalmente, el episodio profundiza en el manejo del cáncer de próstata metastásico de novo. Se consolida el rol de la terapia triple con docetaxel en pacientes de alto volumen y se vislumbra el impacto de la medicina de precisión con la incorporación de inhibidores de PARP en alteraciones de recombinación homóloga o capivasertib en mutaciones de PTEN. Además, se revalida la indicación de radioterapia del tumor primario en enfermedad de bajo volumen, respaldada por los datos de STAMPEDE y STOPCAP. Por último, se examina el paradigma emergente de la interrupción estructurada del bloqueo hormonal en pacientes super-respondedores, marcando una evolución crítica desde la clásica "terapia intermitente" hacia una verdadera desintensificación estratificada.Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.
What if the same type of electromagnetic fields we usually discuss as health risks could actually be used to fight cancer? A new study reveals how precisely controlled EMF exposures killed prostate cancer cells in the lab. I'm R Blank, and in this episode of the Healthier Tech Podcast, I break down groundbreaking research showing how extremely low frequency pulsed electromagnetic fields activated tumor suppressor genes and triggered cancer cell death. This represents a fascinating inversion of the typical EMF narrative -- and it's crucial to understand why therapeutic EMF applications are completely different from the environmental exposures we encounter daily. In This Episode How controlled pulsed electromagnetic fields killed prostate cancer cells in laboratory conditions The specific genetic changes that make this therapy work -- including activation of PTEN and BAX genes Why therapeutic EMF is fundamentally different from environmental EMF exposure What this research means for the future of cancer treatment Featured Study Read the full study: Investigating the expression changes of several key genes in prostate cancer cells under exposure to the ELF pulsed electromagnetic fields See all studies at shieldyourbody.com/research
Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer. Presenters: Cristina Saura Manich, MD, PhD Head, Breast Cancer Unit Medical Oncology Service Vall d'Hebron University Hospital Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain Giampaolo Bianchini, MD Associate Professor, Universita Vita-Salute San Raffaele Head, Breast Cancer Group, Department of Medical Oncology Head, Clinical Translational and Immunotherapy Research IRCCS Ospedale San Raffaele Milan, Italy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion.https://bit.ly/4p6W8gP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast. In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS: trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers
In this EAU Podcast episode, Ass. Prof. Giancarlo Marra (IT), Prof. Derya Tilki (DE) and Prof. Philip Cornford (IE) discuss the latest updates in the 2026 EAU Guidelines on Prostate Cancer.They explore changes in risk stratification, the evolving role of enzalutamide plus ADT in high-risk disease, and emerging diagnostic technologies such as micro-ultrasound and NeuroSAFE. The conversation also highlights advances in personalised treatment approaches for metastatic hormone-sensitive prostate cancer, including BRCA and PTEN-targeted strategies.In addition, the speakers emphasise the growing importance of supportive care, bone protection, and managing long-term treatment-related side effects to improve patient outcomes.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Winning-the-Battle-Against-Side-Effects-Adverse-Event-Management-in-HSPC/57198/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Molecular-Profiling-in-mHSPC-Informing-Treatment-Selection/57199/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Targeting-PTEN-Why-It-Matters/57200/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/De-Novo-mHSPC-Recognizing-the-Patients-Who-Need-More/57195/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/ADT-Intensification-The-Evidence-You-Cant-Afford-to-Miss/57196/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Case-Implementing-ADT-Intensification-in-mHSPC/57197/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
Can you really treat prostate cancer effectively without knowing the genetics? In this episode of BackTable Urology, Dr. Evan Yu and Dr. Tanya Dorff join host Dr. Alan Tan to discuss why genetic testing is essential in personalized prostate cancer care. They discuss when and how to perform germline and somatic testing, address common barriers, and share best practices for counseling patients. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:18 - Who Gets Somatic Testing?06:43 - Patient Barriers to Testing09:00 - Genetic Testing Workflow12:28 - Treating BRCA2 Alterations24:18 - Monitoring Progression: ctDNA vs. PSA vs. Imaging29:32 - Treating mCRPC with ATM Mutations34:39 - CDK12 Classification 37:43 - Closing Takeaways --- More about this episode The doctors explore how BRCA2 and other DNA repair alterations can directly shape treatment decisions, focusing on the roles of PARP inhibitors and platinum therapy in advanced cases. The discussion highlights why both germline and somatic testing are critical for identifying actionable mutations and discuss the nuances of interpreting test results, including current limitations and emerging biomarkers. They also examine challenges such as insurance coverage, patient misconceptions, and workflow integration, as well as the movement toward truly personalized, biology-driven approaches in prostate cancer care. --- Resources Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial:https://pmc.ncbi.nlm.nih.gov/articles/PMC12705445/ Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study:https://www.annalsofoncology.org/article/S0923-7534(25)04936-1/fulltext Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer:https://www.nejm.org/doi/full/10.1056/NEJMoa1903307 ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patientshttps://www.sciencedirect.com/science/article/pii/S0302283825048766 First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer:https://www.nejm.org/doi/abs/10.1056/NEJMoa2502929 PROMISE Registry:https://www.prostatecancerpromise.org/ Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00683-X/abstract --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
This month on Episode 84 of Discover CircRes, host Cindy St. Hilaire highlights articles featured in the April 24th and May 8th issue of Circulation Research. This Episode also features a discussion with Dr Mete Civelek and Dr Noah Perry about their study, Female-Biased Vascular Smooth Muscle Cell Gene Regulatory Networks Predict MYH9 as a Key Regulator of Fibrous Plaque Phenotype. Article highlights: Westhoff, et al. PTEN and PIP3 in AngII-Induced Cardiac Pathology Witmer, et al. Novel Mode of SCN5A-Mitochondrial Crosstalk Ghiringhelli, et al. Light-Controllable Humanized Bioengineered Atria Wang, et al. Exercise-Induced Cardiomyocyte EVs Deliver EPPIR
Featuring an interview with Dr Seth Wander, including the following topics: Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00) Potential role of thymidine kinase testing in monitoring response to therapy (4:56) Interpretation of next-generation sequencing testing; use of targeted therapy (10:59) Phase III lidERA Breast Cancer trial and its implications for the use of giredestrant (14:19) Interpreting plots from the Guardant360® test; future applications of circulating tumor DNA (19:07) Toxicity surrounding use of agents targeting the PAM signaling pathway; treatment for patients with PAM pathway alterations and ESR1 mutations (25:15) Potential role of artificial intelligence in profiling biomarkers; comparative efficacy of first- and later-line use of CDK inhibitors (30:26) Case: A woman in her mid 60s diagnosed with hormone receptor (HR)-positive, HER2-low metastatic breast cancer experiences disease progression after 5 years despite letrozole/ribociclib and is found to have ESR1 mutations, treated sequentially with elacestrant then trastuzumab deruxtecan (39:10) Case: A woman in her mid 50s who previously received treatment for localized disease develops progressive metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer (45:31) Case: A woman in her late 70s with HR-positive, HER2-negative breast cancer who previously received treatment for localized disease is now diagnosed with progressive PTEN-deficient metastatic disease (51:36) Case: A woman in her early 70s with HR-positive, HER2-low metastatic breast cancer and bone metastases initially receives letrozole in combination with abemaciclib, then abemaciclib monotherapy (53:59) CME information and select publications
Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices. Presenters: Nadia Harbeck, MD Breast Cancer Director Department of OB&GYN and Comprehensive Cancer Center Munich LMU University Hospital Munich, Germany Francois-Clement Bidard, MD, PhD Breast Medical Oncology Institut Curie & University of Versailles Paris, France Link to full program:https://bit.ly/4cFd0Xj Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Send us Fan MailWhat if paralysis wasn't permanent—but just a biological system we haven't figured out how to reboot?Dr. Lior Shaltiel, Ph.D. is Chief Executive Officer of NurExone Biologic ( https://nurexone.com/ ), a biotech company pioneering a novel exosome-based platform aimed at repairing the central nervous system.Dr. Shaltiel brings a rare combination of deep scientific training and cross-border biotech leadership. He earned his Ph.D. in molecular pharmacology from Ludwig Maximilian University of Munich, where his research focused on ion channels and retinal biology - early work that connects directly to today's frontier in neuroregeneration.Before stepping into the CEO role, Dr. Shaltiel led R&D programs in advanced drug delivery systems, including liposome-based therapeutics, and worked in global biotech investment and partnerships. He's also the founder of the BioMed MBA program at Hebrew University of Jerusalem, helping train the next generation of biotech leaders.At NurExone, Dr. Shaltiel is advancing the company's ExoTherapy platform - leveraging extracellular vesicles to deliver targeted genetic payloads. Their lead program, ExoPTEN, is an intranasal exosome therapy designed to silence the PTEN gene and promote neuronal regeneration after spinal cord injury - an area where, to date, there are no approved treatments that restore lost function.#biotech #neuroscience #spinalcordinjury #regenerativemedicine #exosomes #stemcells #futureofmedicine #geneediting #biotechinnovation #medicalbreakthrough #neuroregeneration #sciencepodcast #healthtech #longevity #drugdiscovery #PTEN #RNAi #nextgenmedicine #biophysics #medtechSupport the show
Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women's Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors.CME information and select publications here.
Featuring perspectives from Ms Jamie Carroll, Prof Giuseppe Curigliano, Dr Marie E McDonnell and Dr Hope S Rugo, including the following topics: Introduction: Use of On-Body Glucose Monitoring Devices (0:00) Overview of Breast Cancer and Diabetes (9:39) PI3K/AKT/mTOR Pathway and Glucose Metabolism (19:28) Case Presentations — Part 1 (26:02) Current Data with Alpelisib, Capivasertib and Inavolisib (43:51) Prevention and Management of Hyperglycemia (1:02:17) Case Presentations — Part 2 (1:10:24) CME information and select publications
In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas, medical oncologist from the Fred Hutch Cancer Center, who walked through practice-changing and practice-reinforcing data across bladder cancer, kidney cancer, and prostate cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: CREST & POTOMAC: IO-BCG combination data in high-risk BCG-naive NMIBC, both demonstrating a hazard ratio of 0.68 for DFS / EFS. EV-304/KEYNOTE-B15: established EV-Pembrolizumab as the new perioperative standard of care for resectable muscle-invasive bladder cancer regardless of cisplatin eligibility, with a pathological complete response rate of 56% and overall survival hazard ratio of 0.65. LITESPARK-022 & LITESPARK-011: data exploring Belzutifan combinations in adjuvant and refractory RCC settings, while managing key toxicities of anemia and hypoxia. CAPITELLO-281: evaluating capivasertib in PTEN-deficient metastatic hormone-sensitive prostate cancer, where patient related outcomes were reported. Join us for this comprehensive discussion covering the latest GU oncology advances that will directly impact your clinical practice. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #GUASCO2026, #BladderCancer, #RenalCellCarcinoma, #ProstateCancer, #OncBrothers
In this episode of The Behavioral View, Nissa Van Etten, Olivia Teal, Elizabeth Barajas, and Yagnesh Vadgama discuss the evolution of outcomes-based care within applied behavior analysis (ABA). Drawing from extensive experience in both clinical practice and payer systems, Vadgama outlines the differences between traditional fee-for-service models and outcomes-based care frameworks. The panel explores how standardized assessments, aggregate data analysis, and empirically supported dosing recommendations can create greater alignment between providers and payers while maintaining individualized clinical decision-making. The discussion addresses administrative burden, prior authorization processes, value-based payment arrangements, caregiver involvement, social determinants of health, and interdisciplinary collaboration. Emphasis is placed on transparency, data-driven decision making, and protecting the integrity of behavior analytic practice while demonstrating measurable outcomes at both the individual and population levels. This course provides practical insight into how outcomes-based care models may shape the future of ABA service delivery. To earn CEUs for listening, click here, log in or sign up, pay the CEU fee, + take the attendance verification quiz to generate your certificate! Don't forget to subscribe and follow and leave us a rating and review. Show Notes: References Frazier, T. W., Youngstrom, E. A., Speer, L., Embacher, R., Law, P., Constantino, J., Findling, R. L., Hardan, A. Y., & Eng, C. (2014). Validation of proposed DSM-5 criteria for autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 53(1), 28–40. https://doi.org/10.1016/j.jaac.2013.10.012 Frazier, T. W., Klingemier, E. W., Beukemann, M., Speer, L., Markowitz, L., Parikh, S., & Strauss, M. S. (2021). Development and validation of the Autism Impact Measure (AIM). Journal of Autism and Developmental Disorders, 51, 3407–3421. https://doi.org/10.1007/s10803-020-04795-1 Smith, P. C., Sagan, A., Siciliani, L., & Figueras, J. (2023). Building on value-based health care: Towards a health system perspective. Health Policy, 138, 104918. https://doi.org/10.1016/j.healthpol.2023.104918 AI.Measures Scientific Support Ferguson, E. F., Frazier, T. W., Hardan, A. Y., & Uljarević, M. (2025). Challenging behavior domains in individuals with neurodevelopmental genetic syndromes: The role of psychological features. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 0(1), 1-12 Frazier, T. W., Huba, K., Frazier, A. R., Womack, R. A., Youngstrom, E. A., Chetcuti, L., Hardan, A. Y., & Uljarevic, M. (2025). Maximizing accurate detection of divergence from normative expectation in behavioral intervention outcome assessment. Research in Autism, 126, 202646. Frazier, T. W., Youngstrom, E. A., Frazier, A. R., & Uljarevic, M. (2025). A critical appraisal of the measurement of adaptive social communication behaviors in the behavioral intervention context. Behavioral Sciences, 15(6), 722 Frazier, T.W., Helton, M., Akouri, C., Chetcuti, L., Uljarevic, M. (2025) Identifying Reliable Change In Outcome Assessments for Behavioral Intervention. Behavioral Interventions. Frazier, T. W., Dimitropoulos, A., Abbeduto, L., Armstrong-Brine, M., Kralovic, S., Shih, A., Hardan, A. Y., Youngstrom, E. A., Uljarevic, M., Verbal Beginnings, T. (2024). Psychometric evaluation of the Autism Symptom Dimensions Questionnaire. Developmental Medicine and Child Neurology. Frazier, T. W., Busch, R. M., Klaas, P., Lachlan, K., Jeste, S., Kolevzon, A., Loth, E., Harris, J., Speer, L., Pepper, T., Anthony, K., Graglia, J. M., Delagrammatikas, C., Bedrosian-Sermone, S., Beekhuyzen, J., Smith-Hicks, C., Sahin, M., Eng, C., Hardan, A. Y., & Uljarevic, M. (2023). Development of informant-report neurobehavioral survey scales for PTEN hamartoma tumor syndrome and related neurodevelopmental genetic syndromes. Am J Med Genet A, 191(7), 1741-1757. https://doi.org/10.1002/ajmg.a.63195 Frazier, T. W., Crowley, E., Shih, A., Vasudevan, V., Karpur, A., Uljarevic, M., & Cai, R. Y. (2022). Associations between executive functioning, challenging behavior, and quality of life in children and adolescents with and without neurodevelopmental conditions. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2022.1022700 Frazier, T. W., Dimitropoulos, A., Abbeduto, L., Armstrong-Brine, M., Kralovic, S., Shih, A., Hardan, A. Y., Youngstrom, E. A., Uljarevic, M., & Quadrant Biosciences - As You Are Team. (2023). The Autism Symptom Dimensions Questionnaire: Development and psychometric evaluation of a new, open-source measure of autism symptomatology. Developmental Medicine and Child Neurology. https://doi.org/10.1111/dmcn.15497 Frazier, T. W., Dimitropoulos, A., Abbeduto, L., Armstrong-Brine, M., Kralovic, S., Shih, A., Hardan, A. Y., Youngstrom, E. A., Uljarevic, M., Womack, R., Wolf, D., Chappell, N., & Verbal Beginnings Team. (2024). Psychometric Evaluation of the Autism Symptom Dimensions Questionnaire (ASDQ). Developmental Medicine and Child Neurology. Frazier, T. W., Hyland, A. C., Markowitz, L. A., Speer, L. L., & Diekroger, E. A. (2020). Psychometric evaluation of the revised child and family quality of life questionnaire (CFQL-2). Research in Autism Spectrum Disorders, 70. https://doi.org/https://doi.org/10.1016/j.rasd.2019.101474 Frazier, T. W., Khaliq, I., Scullin, K., Uljarevic, M., Shih, A., & Karpur, A. (2022). Development and psychometric evaluation of the open-source challenging behavior scale. Journal of Autism and Developmental Disabilities. https://doi.org/https://doi.org/10.1007/s10803-022-05750-5 Frazier, T. W., Krishna, J., Klingemier, E., Beukemann, M., Nawabit, R., & Ibrahim, S. (2017). A Randomized, Crossover Trial of a Novel Sound-to-Sleep Mattress Technology in Children with Autism and Sleep Difficulties. J Clin Sleep Med, 13(1), 95-104. https://doi.org/10.5664/jcsm.6398 Frazier, T. W., Busch, R. M., Klass, P., Crowley, E., Lachlan, K., Jeste, S., Kolevzon, A., Loth, E., Harris, J., Pepper, T., Anthony, K., Graglia, J. M., Helde, K., Delagrammatikas, C., Bedrosian-Sermone, S., Smith-Hicks, C., Sahin, M., Eng, C., Hardan, A. Y., . . . Uljarevic, M. (2024). Quantifying Neurobehavioral Profiles across Neurodevelopmental Genetic Syndromes and Idiopathic Neurodevelopmental Disorders. Developmental Medicine and Child Neurology. https://doi.org/https://doi.org/10.1111/dmcn.16112 Uljarevic, M., Cai, R. Y., Hardan, A. Y., & Frazier, T. W. (2022). Development and validation of the Executive Functioning Scale. Front Psychiatry, 13, 1078211. https://doi.org/10.3389/fpsyt.2022.1078211 Uljarevic, M., Spackman, E. K., Cai, R. Y., Paszek, K. J., Hardan, A. Y., & Frazier, T. W. (2022). Daily living skills scale: Development and preliminary validation. Frazier, T. W., Helton, M., Akouri, C., Chetcuti, L., & Uljarevic, M. (2025). Identifying reliable change in outcome assessments for behavioral interventions. Behavioral Interventions, 40, e70007. https://doi.org/https://doi.org/10.1002/bin.70007 Resources CentralReach. (n.d.). AI Measures (AIM). https://centralreach.com
In this episode of the Oncology Brothers podcast we navigated the rapidly evolving treatment landscape of Metastatic Hormone Receptor-Positive Breast Cancer. We were joined by Dr. Kevin Kalinsky, Director of the Breast Cancer Program at the Winship Cancer Institute, Emory University, to discuss the implications of new targeted therapies, optimal sequencing strategies, and practical toxicity management. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • YouTube: https://www.youtube.com/@oncologybrothers • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ The discussion covered: • The critical role of NGS testing (tissue vs. liquid biopsy) in identifying PIK3CA, ESR1, AKT1 and PTEN alterations. • Frontline management of high-risk, endocrine-resistant disease with the inavolisib triplet (INAVO120) and its overall survival benefit. • Choosing between CDK4/6 inhibitors (abemaciclib vs. ribociclib) in de novo metastatic disease. • Post-CDK4/6 inhibitors on progression we covered, the use of oral SERDs (imlunestrant) and AKT inhibitors (capivasertib). • The "ADC explosion", sequencing T-DXd (DESTINY-Breast06), sacituzumab govitecan (TROPiCS-02), and datopotamab deruxtecan (TROPION-Breast01). • Clinical pearls for managing toxicities: stomatitis, hyperglycemia, rash, neutropenia, and ILD. Join us as we break down the latest data and provide actionable insights for the practicing oncologist. Don't forget to subscribe for more episodes in our breast cancer algorithm series! #MetastaticBreastCancer, #HRPositive, #ADCsequencing, #PIK3CA-AKT, #OncologyPodcast, #OncologyBrothers
Port wine birthmark treatment -PTEN hamartoma tumor syndrome -Nanobubble technology for ichthyosis -Reactive granulomatosis dermatitis in kids -Cardiac issues in X-linked ichthyosis -Timolol for chronic wounds - Check out Luke's Urticaria CMEexperience! aaaaicsu.gathered.com/invite/KQe1wPZbJY Learnmore about the U of U Dermatology ECHOmodel! physicians.utah.edu/echo/dermatology-primarycare Want to donate to the cause? Do so here!Donate to the podcast: uofuhealth.org/dermasphereCheck out our video content on YouTube:www.youtube.com/@dermaspherepodcastand VuMedi!: www.vumedi.com/channel/dermasphere/The University of Utah's DermatologyECHO: physicians.utah.edu/echo/dermatology-primarycare -Connect with us!- Web: dermaspherepodcast.com/ - Twitter: @DermaspherePC- Instagram: dermaspherepodcast- Facebook: www.facebook.com/DermaspherePodcast/- Check out Luke and Michelle's other podcast,SkinCast! healthcare.utah.edu/dermatology/skincast/ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:- Kikoxp.com (a social platform for doctors to share knowledge)- www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!
Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: AKT inhibitors for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (0:00) Radioligand-directed therapy for PSMA-positive metastatic hormone-sensitive prostate cancer (8:18) Radiation therapy in combination with enzalutamide for high-risk localized prostate cancer (13:14) CME information and select publications
Suchdol na Konicku najdeme na svahu Drahanské vrchoviny, který odsud pomalu klesá do nivy řek Romže a Okluky. Nejvyšší část katastru obce však přesahuje i 500 metrů nadmořské výšky.Všechny díly podcastu Od Pradědu na Hanou můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.
In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care. Episode Highlights: PSMAddition: Explore the benefits of lutetium PSMA in metastatic hormone-sensitive prostate cancer, including improved radiographic progression-free survival when combined with ADT and ARPIs. Capitello-281: Highlights the use of Capivasertib in patients with PTEN loss, showing significant improvements in radiographic PFS. Potomac: Examining the role of durvalumab + BCG in high-risk non-muscle invasive bladder cancer, and the promising results from the Keynote 905 study involving enfortumab and pembrolizumab. IMVigor011: Delved into showcasing how ctDNA-guided therapy with atezolizumab can improve survival outcomes. Stay tuned as we navigate the complexities of treatment options, side effects, and the importance of patient-centered decision-making in oncology. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #ESMO2025 #GUOncology #LutetiumPSMA #Enfortumab #BladderCancer #ProstateCancer #OncologyBrothers
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD About 40 percent of patients with metastatic HR+/HER2- breast cancer have an activating mutation in the PIK3CA gene,1,2 which plays a key role not only in tumor growth, but also in driving resistance to endocrine therapy.3-5 And while there are several FDA-approved PI3K pathway-targeted agents for patients with PIK3CA tumor mutations,6-8 they come with challenges, like modest efficacy and on-pathway effects.9-12 Given this unmet need, the ReDiscover trial evaluated the investigational agent RLY-2608 in combination with fulvestrant in in patients with PIK3CA-mutated HR+/HER2- aBC previously treated with a CDK4/6 inhibitor.13 Joining Dr. Charles Turck to share updated safety and efficacy data from the trial is Dr. Sarah Sammons, a Senior Physician at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School in Boston. References: Vasan N, Cantley LC, Vasan N, Cantley LC. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat Rev Clin Oncol. 2022;19(7):471-485. doi:10.1038/s41571-022-00633-1 Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi:10.1038/nature11412 Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor …
Friday, August 29th, 2025. Week 35. 5th Annual Gala was a great success! cureSYNGAP1.org/Gala5 Sad to miss it? Join us in Boston or South Carolina. Deadline for Boston is 9/3 for tickets. Beacon of Hope September 12, 2025 - Boston, MA cureSYNGAP1.org/Beacon25 Scramble for SYNGAP October 4, 2025 - Greer, SC cureSYNGAP1.org/Scramble SRF is active in Lisbon at #IEC2025 thank you KD, JA, VA! Hi Dr. Knowles! We are at Booth #17 https://www.linkedin.com/posts/victoria-arteaga-26913433_syngap1-familyjourney-resilience-activity-7366951726001606657-6pcM #Bexicaserin News: New data from the PACIFIC Study, LP352-202, Open Label Extension (OLE) will be presented at the 36th International Epilepsy Congress (IEC) in Lisbon, Portugal (Aug 30 - Sept 3, 2025). The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress Bexicaserin, which has been granted Breakthrough Therapy designation by the FDA, demonstrated reductions in countable and total motor seizure frequency in the extension study comparable to reductions seen in the Phase 1b/2a PACIFIC trial, reinforcing durability of response and validating its progression to Phase 3 trials. Additional data will be presented from the audiogenic seizure model and the GAERS absence epilepsy model, investigating sudden unexpected death in epilepsy (SUDEP), and seizure reduction respectively. During the OLE, a median reduction of 59.3% in countable motor seizure frequency was observed, with 55% of participants experiencing reductions of ≥50% compared to the baseline before the PACIFIC trial. This trial, EMERALD and other studies all at https://curesyngap1.org/resources/studies/ See and comment on Vicky's recent post on her 7 year SYNGAP1-iversary: https://www.linkedin.com/posts/victoria-arteaga-26913433_syngap1-familyjourney-resilience-activity-7366951726001606657-6pcM Join Citizen Health, we are at 275! We should double that. https://www.citizen.health/partners/srf DSCIII Renewed to include SYNGAP1 alongside TSC, SHANK3 (aka PMD) and PTEN. CFC Starts on 9/1 https://curesyngap1.org/events/fundraisers/combined-federal-campaign-2025/
“She's triple negative and has a very, very aggressive tumor. Instead of going on spring break that year, she sat in our chemo room and got chemo. Her friends from college are good to try to keep her involved and try to surround her and encourage her, but they're right now in very, very different spots in their lives. She's fighting for her life; her friends are fighting for the grade they get in a class—and that's different,” ONS member Kristi Orbaugh, MSN, NP, AOCN®, AOCNP®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about metastatic breast cancer in adolescent and young adult patients. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 This podcast is sponsored by Lilly and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 354: Breast Cancer Survivorship Considerations for Nurses Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities Episode 307: AYAs With Cancer: Financial Toxicity Episode 300: AYAs With Cancer: End-of-Life Care Planning ONS Voice articles: ‘Cancer Ghosting' May Add Another Layer of Emotional Burden for Patients Discoveries in Race-Related Breast Cancer Biomarkers May Improve Precision Treatments What Is HER-2-Low Breast Cancer? What Oncology Nurses Need to Know About Supporting AYAs With Cancer ONS books: Guide to Breast Cancer for Oncology Nurses Oncology Nursing Forum articles: An Integrative Review of the Role of Nurses in Fertility Preservation for Adolescents and Young Adults With Cancer Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers ONS huddle cards: Altered Body Image Fertility Preservation Sexuality Other ONS resources: Breast Cancer Learning Library Fertility Preservation in Individuals With Cancer ONS Biomarker Database American Cancer Society's breast cancer resources American Society of Clinical Oncology continuing education resources Elephants and Tea Life, Interrupted Livestrong National Cancer Institute's breast cancer resources Stupid Cancer Young Survival Coalition To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we use ‘adolescent and young adult,' we're really talking about age 19–35. Some groups will say 15–39, but right around that age. When we think about that age, think about what all could be going on during those ages. Late teenagers, they may be going off to college, they may be graduating high school, trying to set up their own life, trying to become independent from mom and dad. If you're talking about early to mid 30s, you could be talking about young parents, young career folks. So, just setting that into place makes you realize this can be a very tumultuous time for folks.” TS 2:06 “Unfortunately, this group tends to have more aggressive subtypes. We see more triple-negative in this group. We see more hormone-negative, HER2-positive in this group. Normal breast cancer cells should be stimulated by hormone. They are stimulated by hormones. So when you have a breast cancer cell that is not driven by hormones, it's much more difficult to treat. We tend to see more aggressiveness in these tumors. We also see a higher incidence in non-Caucasian folks in this age group compared to the older age groups.” TS 4:53 “I think we have gotten much better about understanding the importance of fertility preservation and getting reproductive endocrinologists in, sooner rather than later. If we have earlier-stage cancers and we have patients that want to try to preserve eggs, preserve fertility, sperm banking. … If you have that time to talk to them—maybe a 21-year-old—the primary thing on her mind is not how many children she wants to have one day. Maybe she's not even thought about having kids yet. It's still a question you need to [ask]. Do you want to try to preserve fertility? Do you want to try to harvest some eggs? That's a conversation that needs to be had and is very, very important for that age group.” TS 10:35 “One thing that helps is if you can get them [into] reputable support groups with people their own age that are going through what they're going through. Someone else that doesn't have hair, someone else that isn't going to make it to the big board meeting or isn't going to get the promotion this year because they've had to take a medical leave. Someone else that understands it differently.” TS 16:47 “In breast cancer, many of those biomarkers just get reflexed. And what I mean by reflexed is a breast cancer pathology comes through, or a breast cancer specimen comes through, and it just automatically gets tested for X, Y, Z. HER2 and of course ER/PR. Now we understand that we don't just need to know whether they're HER2 positive or HER2 negative. We need to know: What is the IHC score? And even if the IHC score is zero, is there any membrane staining? And then we need to know what's their ESR1, their PTEN, their AKT, their PIK3CA. Those are so important to know.” TS 18:11 “I think it's important to try to remember what our priorities were when we were in our 20s—what our priorities were when we were starting out as young mothers or starting out our career. Because that's where these folks are. … I can't imagine in the midst of college, when I'm trying to be independent, to suddenly have to be at home and rely on my mom to take me to my chemo appointment. … So I think one really important bias is to remember where they are in the developmental stages of life. They're not 40-something. They haven't lived X amount of life, and we need to take a step back and try to remember when we were their age, what was important to us? Where were our priorities at that point? And then hear them when they're telling us what's important to them.” TS 29:22 “From a female standpoint … we frequently throw these patients into menopause or have early menopausal symptoms, and I think we forget how devastating that can be. … They now are at higher risk for osteopenia or osteoporosis. … And then we tell people, ‘Be as normal as possible, get back and do those normal things.' Well, they're in a relationship, and they want to be intimate [but] suddenly having sexual intercourse is incredibly painful. Or if it's not painful, sometimes they've just lost pure interest in that. They don't feel confident about their body. All of those things need to be addressed because patients are trying to live each day as normally as possible.” TS 31:55
BUFFALO, NY – July 9, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 25, 2025, titled “Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms.” Researchers from the University of Cincinnati and Cincinnati Veterans Affairs Medical Center reviewed current research on why Epidermal Growth Factor Receptor (EGFR)-targeted therapies often fail in breast and head and neck cancers. The article by Shreya Shyamsunder, Zhixin Lu, Vinita Takiar, and Susan E. Waltz explores how cancer cells evade these treatments by activating alternative survival pathways. This review offers an in-depth look at the molecular barriers to EGFR inhibition and provides insights that could inform the development of more effective and durable treatments. EGFR is a critical protein that regulates cell growth and survival, and it is frequently overexpressed in breast and head and neck cancers. Although therapies targeting EGFR showed early promise, resistance has become a significant challenge. In breast cancer, resistance mechanisms include the movement of EGFR from the cell surface into the nucleus, where it promotes DNA repair, as well as ligand-dependent activation that helps tumor growth despite therapy. In head and neck cancers, resistance often arises from inflammatory signaling through the TLR4-MyD88 pathway and the loss of tumor suppressor genes like PTEN, which allow cancer cells to bypass EGFR inhibition. The review also describes how tumor cells in both cancers commonly activate other receptor tyrosine kinases (RTKs), such as MET, AXL, and RON, to continue growing even when EGFR is blocked. By analyzing these resistance mechanisms, the authors highlight combination therapies from current research that target EGFR and other key molecular pathways. Strategies such as dual inhibition of EGFR and MET or blocking inflammation-driven survival signals may enhance treatment outcomes. Several clinical trials are evaluating these approaches in patients. For example, in breast cancer, combinations of EGFR inhibitors with chemotherapy and immune checkpoint inhibitors are being tested to improve responses, particularly in triple-negative breast cancer. In head and neck cancers, trials are investigating EGFR-blocking antibodies like cetuximab combined with immunotherapies such as pembrolizumab and nivolumab. These efforts aim to overcome resistance and provide more effective treatment options for patients with EGFR-driven tumors. The review also emphasizes the necessity of identifying biomarkers to predict which patients are most likely to benefit from EGFR-based therapies. “A recent phase 1 study has shown that patients with recurrent or metastatic head and neck cancer who received BCA101, a bifunctional dual targeting drug that targets EGFR and TGF-β in combination with pembrolizumab, were able to achieve an overall response rate of 65%.” This work brings together current knowledge about EGFR resistance and illustrates the difficulties involved in treating breast and head and neck cancers. By mapping the many ways tumors overcome EGFR inhibition, the review highlights opportunities for more tailored and effective treatments in the future. DOI - https://doi.org/10.18632/oncotarget.28747 Correspondence to - Susan E. Waltz - susan.waltz@uc.edu, and Vinita Takiar - takiarva@ucmail.uc.edu Video short - https://www.youtube.com/watch?v=RD2W-F3_aX4 About Oncotarget: Website - https://www.oncotarget.com Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
People with the syndrome, caused by variants in the gene PTEN, often have autism or cancer, or both, but it depends on the genetic diversity encoded in the components of distinct cell signaling pathways, according to a new study.
Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications
Bugün 9 nisan 2025 #doğatakvimi
BUFFALO, NY - March 25, 2025 – A new #review was #published in Oncotarget, Volume 16, on March 13, 2025, titled “Signaling pathway dysregulation in breast cancer." In this review article, Dinara Ryspayeva and colleagues from Brown University provide a detailed look at how breast cancer cells change the way they communicate and grow—helping tumors survive, spread, and resist treatment. The review highlights how certain gene mutations and disrupted signaling pathways influence therapy response across different types of breast cancer. It also outlines current treatment strategies and clinical trials, offering insights that could improve care for patients with aggressive or hard-to-treat cancers. Breast cancer is the most common cancer in women and a major cause of cancer-related deaths worldwide. While many patients respond to treatment at first, some cancers return or stop responding. The review explores how signaling disruptions inside tumor cells are often behind these setbacks. The authors discuss several major pathways involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch, NF-κB, and the DNA damage response (DDR). These pathways help control cell growth, division, DNA repair, and survival. When altered by mutations or other changes, they can promote tumor progression and resistance to treatment. One of the most disrupted pathways is PI3K/Akt/mTOR. It plays a central role in cell growth, but in many breast cancers—especially hormone receptor-positive and HER2-positive types—it becomes overactive due to gene mutations, or the loss of a tumor-suppressing protein called PTEN. “Up to 25–40% of BC cases exhibit variations that hyperactivate the PI3K/Akt/mTOR pathway, underscoring its critical role in oncogenesis.” Another key pathway, RAS/RAF/MEK/ERK, can also promote tumor growth. Even without mutations, it may become active when primary pathways are blocked, particularly in HER2-positive and triple-negative breast cancers. The review also highlights several new and emerging treatments aimed at blocking down these signaling pathways. Some drugs are already approved, while others are in clinical trials. The authors suggest that combining different treatments may help stop multiple pathways at once, making it harder for cancer cells to adapt. Matching treatments to each tumor's unique genetic changes could also improve patient outcomes. This comprehensive review gives researchers and clinicians a clearer understanding of how breast cancer resists treatment and where future therapies should focus. A better understanding of these disrupted signaling systems could lead to more personalized and effective treatments for patients facing aggressive or recurring disease. DOI - https://doi.org/10.18632/oncotarget.28701 Correspondence to - Dinara Ryspayeva - dinara_ryspayeva@brown.edu Video short - https://www.youtube.com/watch?v=ppFVGwdztHI Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
SPOILERS AHEAD! Hey all! One thing both Mike and I love is the MCU... so when we sat down to record Boozy the other night we were both just buzzing about Captain America: Brave New World! We had to record it because, well, we never get tired of hearing our own voices. This is a rare MAIN FEED bonus ep! Want to talk Captain America? Join us on Discord! Are you enjoying the show? www.patreon.com/ptebb Connect with us on Discord, Facebook, Twitter, IG, etc… at www.ptebb.com Don't forget – Leave us a 5 Star Rating and write us a review Enjoy The Show!
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VMG865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 5, 2026.Targeting PIK3CA/AKT1/PTEN and Other Alterations in HR+, HER2- MBC: Navigating the Evidence and Guidance for Use In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VMG865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 5, 2026.Targeting PIK3CA/AKT1/PTEN and Other Alterations in HR+, HER2- MBC: Navigating the Evidence and Guidance for Use In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VMG865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 5, 2026.Targeting PIK3CA/AKT1/PTEN and Other Alterations in HR+, HER2- MBC: Navigating the Evidence and Guidance for Use In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
In this JCO Article Insights episode, Giselle de Souza Carvalho provides a summary on "Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies" by Bhardwarj, et al and "US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations" by Dilawari et al published in the Journal of Clinical Oncology. TRANSCRIPT Giselle Carvalho: Hello and welcome to JCO Article Insights episode for the December issue of the Journal of Clinical Oncology. I'm your host Giselle Carvalho, Medical Oncologist in Brazil focusing on breast cancer and melanoma skin cancers and one of the ASCO Editorial Fellows at JCO this year. Today, I will be discussing two articles. The first one is “Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies,” and the second one is the “US FDA Approval Summary on Capivasertib with Fulvestrant for HR-positive HER2-negative Locally Advanced or Metastatic Breast Cancer with PIK3CA/AKT1/PTEN Alteration.” As we know, 65% to 70% of all breast cancers are HR-positive HER2-negative and this is also the most common subtype of metastatic breast cancer. The current standard of care for frontline therapy of patients with luminal metastatic disease is a CDK4/6 inhibitor in combination with endocrine therapy. However, as new endocrine and targeted therapies gain approval, choosing the best systemic therapy upon disease progression after frontline therapy is a topic of ongoing debate. Nearly 40 to 50% of HR-positive breast cancers have actionable genomic alterations and molecular testing should be a routine recommendation for patients with metastatic HR-positive HER2-negative disease. This can be performed repeating tissue biopsy at the time of progression or from archival tissue. Treatment options after progression on CDK4/6 inhibitors include alpelisib in combination with fulvestrant in patients with PIK3CA mutant tumors as seen in the SOLAR-1 trial, or capivasertib with fulvestrant in patients with a tumor mutation in (PI3K)–AKT–PTEN pathway as seen in the CAPItello-291 study, which will be discussed further. In approximately 30% of patients, progression on frontline endocrine plus CDK4/6 inhibitor treatment is caused by endocrine resistance, frequently involving activating mutations in ESR1. For those tumors, elacestrant, an oral SERD is an option as demonstrated in the EMERALD trial. For patients with a BRCA mutation, PARP inhibitors represent another option. If no mutations are detected, everolimus, an mTOR inhibitor, can be used based on the BOLERO-2 results. The phase 2 MAINTAIN and PACE trials, along with the phase 3 postMONARCH trial support changing the endocrine therapy backbone with or without switching the CDK4/6 inhibitor. In less resourced areas, fulvestrant monotherapy is still an option to delay cytotoxic chemotherapy, though its efficacy is limited when used as a single agent. Finally, after progression on at least one line of chemotherapy, antibody drug conjugates including sacituzumab govitecan or trastuzumab deruxtecan may be an option. Now focusing on the PI3K AKT PTEN signaling pathway, activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN occur in approximately half of luminal breast cancers. In June 2023, the CAPItello-291 trial was published and treatment with fulvestrant plus capivasertib, a PTEN AKT inhibitor, demonstrated a 3.6 month PFS benefit compared to fulvestrant alone, regardless of the presence of AKT pathway alterations. However, for those with tumors without AKT pathway alteration, an exploratory analysis showed that although there was a numerical improvement in PFS, it did not meet statistical significance, indicating that the biomarker positive population primarily drove the positive results noted in the overall population. Therefore, capivasertib plus fulvestrant was approved by the US FDA in November 2023 exclusively for patients with PI3K/AKT1/PTEN tumor alterations after progression on an aromatized inhibitor with or without a CDK4/6 inhibitor. The approved schedule of capivasertib is slightly different from that of other agents used in breast cancer. It is 400 milligrams taken orally twice a day for four days per week every week in a 28-day cycle in combination with fulvestrant. Diarrhea, rash and hyperglycemia were the most commonly reported grade three or four adverse events in the interventional group. I would like to highlight that even though the CAPItello trial excluded patients with glycosylated hemoglobin levels higher than 8% or those diagnosed with diabetes who required insulin, hyperglycemia occurred in 19% of biomarker positive patients treated with capivasertib, with nearly 2% of this population experiencing grade 3 or 4 hyperglycemia and some patients experiencing life threatening outcomes such as diabetic ketoacidosis. By way of comparison, hyperglycemia of any grade was three times higher with alpelisib therapy in the SOLAR-1 trial, occurring in 64% of the patients and grade three or higher hyperglycemia was seen in 37% of the patients. Diarrhea was the most common treatment related adverse event experienced by 77% of the biomarker positive population. Prompt use of the antidiarrheal drugs when needed, such as loperamide must be encouraged as untreated diarrhea can lead to dehydration and renal injury. Cutaneous rash occurred in 56% of the biomarker positive population in the interventional group and 15% experienced a grade 3 or 4 rash. Nearly half of the patients with cutaneous adverse reactions required treatment and this was the leading reason for dose reduction of capivasertib. In the biomarker positive population, the improvement in medium PFS were 4.3 months by investigator assessment. Overall survival data from the CAPItello-291 trial is still immature, but quality of life data was recently published in September this year and was assessed by the 30 item QLQ C30 questionnaire and the QLQ BR23, the breast module. According to Oliveira et al, global health status and quality of life were maintained for a longer period with capivasertib fulvestrant than with placebo fulvestrant except for symptoms of diarrhea which were significantly worse in the capivasertib group. The median time of deterioration of global health status and quality of life was twice as long in the capivasertib group being almost 25 months versus 12 months in the placebo fulvestrant group. These data reinforced the use of capivasertib in combination with fulvestrant for the treatment of HR-positive HER2-negative advanced breast cancer patients with PIK3CA/AKT1/PTEN tumor alterations who have progressed after an aromatase inhibitor-based therapy with or without a CDK4/6 inhibitor. Thank you for listening to JCO Article Insights. This is Giselle Carvalho. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. See you next time. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.
Predicting how influenza viruses will evolve, how deserts decompose matter despite the dry, what worms are revealing about a gene linked to autism, and what makes mice fearful of cat smells. Dr Chris Smith talks to the authors of the latest leading research in eLife... Get the references and the transcripts for this programme from the Naked Scientists website
Featuring perspectives from Dr Komal Jhaveri and Dr Hope S Rugo, including the following topics: Introduction: PI3K/AKT/PTEN Pathway and Resistance to Endocrine Therapy (0:00) First-Line Therapy for HR-Positive Metastatic Breast Cancer (mBC) Harboring PI3K/AKT/PTEN Mutations (7:04) Treatment Options for Recurrent mBC with PI3K/AKT/PTEN Mutations (24:11) Beyond the Guidelines Survey (35:36) Faculty Case Presentations (51:27) CME information and select publications
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PI3KAKTPTENmBC24).
We break down what's going on with these crazy markets and volatility, what you should do, and how to trade. We discuss the most active equity options for the day including PTEN, NU. We talk about earnings volatility this week in RDDT, RIVN, LYFT, UBER, HOOD. We also look at unusual options activity in CFG, GOTU, REAL. Uncle Mike Tosaw discusses managing draw downs while staying invested. With your hosts: Mark Longo, The Options Insider Media Group Mark "The Greasy Meatball" Sebastian, The Option Pit "Uncle" Mike Tosaw, St. Charles Wealth Management Options are not suitable for all investors and carry significant risk. Option investors can rapidly lose the value of their investment in a short period of time and incur permanent loss by expiration date. Certain complex options strategies carry additional risk. There are additional costs associated with option strategies that call for multiple purchases and sales of options, such as spreads, straddles, among others, as compared with a single option trade. Prior to buying or selling an option, investors must read and understand the “Characteristics and Risks of Standardized Options”, also known as the options disclosure document (ODD) which can be found at: www.theocc.com/company-information/documents-and-archives/options-disclosure-document Supporting documentation for any claims will be furnished upon request. If you are enrolled in our Options Order Flow Rebate Program, The exact rebate will depend on the specifics of each transaction and will be previewed for you prior to submitting each trade. This rebate will be deducted from your cost to place the trade and will be reflected on your trade confirmation. Order flow rebates are not available for non-options transactions. To learn more, see our Fee Schedule, Order Flow Rebate FAQ, and Order Flow Rebate Program Terms & Conditions. Options can be risky and are not suitable for all investors. See the Characteristics and Risks of Standardized Options to learn more. All investing involves the risk of loss, including loss of principal. Brokerage services for US-listed, registered securities, options and bonds in a self-directed account are offered by Open to the Public Investing, Inc., member FINRA & SIPC. See public.com/#disclosures-main for more information.
In this episode, we explore Autism developing in the embryo. We will review a couple Scientific papers discussing specific time frames of development within the embryo based on each trimester and specific cellular abnormal processes occurring. We will connect previous biological and environmental components and how it influences the creation of Autism and previous episodes of From the Spectrum podcast.Remember in the Cause of Autism episode- Light, Water, Magnetism, Periodic Elements, Vitamins, and Proteins because they are involved. During the episode, we review risk-genes and how this could be the wrong direction for Autism research. As a counter, I provide where research and funding needs to focus- pregnancy.Cause of Autism https://podcasts.apple.com/us/podcast/from-the-spectrum-finding-superpowers-with-autism/id1737499562?i=1000662271496Eric Courchesne https://profiles.ucsd.edu/eric.courchesnePrenatal Origins of ASD: The When, What, and How of ASD Development https://www.cell.com/trends/neurosciences/fulltext/S0166-2236(20)30051-5?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0166223620300515%3Fshowall%3DtrueThe ASD Living Biology: from cell proliferation to clinical phenotype https://www.nature.com/articles/s41380-018-0056-yLeukocytes and Melanin Pigmentation https://core.ac.uk/download/pdf/81931995.pdfmTOR and PTEN https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743803/Cancer Drug for "Autism" https://neurosciencenews.com/asd-cognition-cancer-pharmacology-26481/0:00 Autism and the Embryo; Review of previous developmental milestones, and the processes and "ingredients" used in our Biology5:45 Cellular processes; ASD Living Biology; becoming the complex living organism8:17 1st Trimester: Proliferation, neurogenesis, migration8:46 2nd Trimester: Neurite overgrowth, synaptogenesis and synaptic function9:12 3rd Trimester: Neural networks9:33 Epoch 1 and 213:04 Scientific Literature; risk-genes; send research and funding to pregnancy17:57 Abnormal brain development in the embryo21:39 Excitation and the risk-genes and consequences to the Nervous System24:36 Be cautious of research direction; MEDICATION and MEDICAL PARADIGM RANT29:32 Connecting Light and Abnormal Development across the Body- Example Melanin and Leukocytes33:12 Recap on the Past 3 episodes36:00 Reviews/Ratings and Contact InfoX: https://twitter.com/rps47586Facebook: https://www.facebook.com/fromthespectrum.podcastEmail: info.fromthespectrum@gmail.com
Welcome back to the pub! This is the first of 4 episodes where Mike will be drinking nothing but Malort after losing his Oscar bet to Chris yet again! Chris is hosting this game as another Chris is taking on Mike in a head to head matchup for the ages. Are you enjoying the show? www.patreon.com/ptebb Connect with us on Discord, Facebook, Twitter, IG, etc… at www.ptebb.com Don't forget – Leave us a 5 Star Rating and write us a review Enjoy The Show!
In this episode, we explore three regions associated with social awareness- the medial Prefrontal Cortex, the Anterior Cingulate Cortex, and the Insula. We review the functions of each, the interactions between each region, and the inputs and bi-directional connections to some crucial areas of the brain. In large part, we will review adaptive responses and cover some scientific literature on these regions and the implications to Autism.https://molecularautism.biomedcentral.com/articles/10.1186/s13229-024-00593-6https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354837/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766703/#:~:text=Schematic%20structure%20of%20different%20regions,and%20infralimbic%20cortex%20(IL).https://www.cell.com/neuron/fulltext/S0896-6273(12)01108-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0896627312011087%3Fshowall%3Dtruehttps://www.nature.com/articles/s42003-024-06016-9https://www.sciencedirect.com/science/article/pii/S0149763409000815?via%3Dihub#aep-section-id15https://www.tandfonline.com/doi/full/10.1080/17470919.2023.2242095https://www.sciencedirect.com/science/article/abs/pii/S0006322308011578(0:00) Intro; mPFC, ACC, and Insula(3:26) mPFC, Excitation / Inhibition; CNTNAP2, SHANK3, Neuroligin, and PTEN(7:42) Functions of mPFC and a primary dive into Adaptive Responses; Neuromodulators(13:52) ACC(15:23) the mPFC and ACC lead the way(19:29) Scientific Studies on Theory of Mind Task and Sensory Processing(21:52) Insula(26:49) Scientific Study: Eye Gaze, Social Attention, Social Cognition, Observational Learning(30:11) Social and Nonsocial Studies- different areas for Autistics versus Non-Autistic(32:38) A study using 6-week-old Infants, attentional biases and sensorimotor and different brain areas(35:05) Wrap Upemail: info.fromthespectrum@gmail.com
© 2020-2026 Ivy Podcast Discovery LLC
